Targeting a novel metabolic vulnerability of non-small cell lung cancer to fatty acid oxidation surmounts chemoresistance

Drug Resistance Updates · Published 2026-08-02 · DOI 10.1016/j.drup.2026.101462

Free full text

Authors (25)

Simona Fontana, Dimas Carolina Belisario, Claudia Giannotta, Luca Alessandri, Sabrina Digiovanni, Angelo Meoli, Francesco Passiglia, Alessandra Merlini, Giulianmichela Di Palma, Martina Perin, Francesca Napoli, Maddalena Arigoni, Muhlis Akman, Elisa Balmas, Costanzo Costamagna, Iris Chiara Salaroglio, Joanna Kopecka, Alessandro Bertero, Luisella Righi, Massimo Massaia, Raffaele Calogero, Silvia Novello, Giorgio Vittorio Scagliotti, Yehuda G. Assaraf, Chiara Riganti

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Fontana, S., Belisario, D., Giannotta, C., et al. (2026). Targeting a novel metabolic vulnerability of non-small cell lung cancer to fatty acid oxidation surmounts chemoresistance. Drug Resistance Updates. https://doi.org/10.1016/j.drup.2026.101462

Related articles

• Lung cancer, platinum analog-based frontline treatment and pharmacogenetic limitations · Personalized Medicine · 2024 · Cites or is cited by this article
• Tailored HER2 ECD mRNA-LNP vaccines boost CD8+ T cell-mediated antitumor immunity for HER2-positive tumor suppression · Drug Resistance Updates · 2026 · Same journal
• Resistance to CAR-based cell therapy: Mechanisms and overcoming strategies · Drug Resistance Updates · 2026 · Same journal
• Low dose radiation induces new protein synthesis that promotes cancer radiotherapy resistance · Drug Resistance Updates · 2026 · Same journal
• Long-term outcomes and exploratory analysis from a randomized phase 3 trial of radiation dose escalation in definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma · Drug Resistance Updates · 2026 · Same journal
• ZBED6-Driven Nucleotide Metabolic Reprogramming Improves Sensitivity to anti-PD1 Therapy in NK/T Cell Lymphoma · Drug Resistance Updates · 2026 · Same journal
• PRKCA and ABCB1 dual-enriched exosomes are key drivers of drug resistance in chronic myeloid leukemia · Drug Resistance Updates · 2026 · Same journal
• Mechanistic analysis on epigenetic programming of tumor drug resistance · Drug Resistance Updates · 2026 · Same journal
• NHE6-driven endosome-autophagy axis confers proteasome inhibitor resistance in multiple myeloma · Drug Resistance Updates · 2026 · Same journal
• Resensitizing drug-resistant cancers by co-targeting apoptosis and mitochondrial stress pathway · Drug Resistance Updates · 2026 · Same journal